PALISADE BIO, INC. - 8-K Filing
Palisade Bio reported Q1 2026 financial results with a net loss of $9.6 million, or $0.05 per share, compared to a net loss of $2.23 million, or $0.47 per share in the same period last year. R&D expenses rose to $6.4 million from $1.0 million due to clinical trials for PALI-2108 and increased employee costs. The company holds $132.6 million in cash as of March 31, 2026, sufficient to fund operations through key Phase 2 trial readouts expected by late 2027. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)
Tickers: $PALI